fourteen News

FIDIA Farmaceutici to Attend the 32nd Annual J.P. Morgan Investors Healthcare Conference

ABANO TERME, Italy and PARSIPPANY, New Jersey, January 6, 2014 /PRNewswire/ —

FIDIA Farmaceutici S.p.A., the Italian pharmaceutical company leader in hyaluronic acid (HY) – based products, announced today that they will be present at the 32nd Annual J. P. Morgan Investors Healthcare Conference. The conference will take place on Monday, January 13, 2014, through Thursday, January 16, 2014, at the Westin St. Francis Hotel in San Francisco.

The annual J.P. Morgan Healthcare Conference is the largest healthcare investment event in the industry. The expected attendance includes more than 300 companies, both public and private, to deliver presentations to more than 3,000 investors. “The Conference provides a unique opportunity to showcase FIDIA’s unique capabilities, innovative technology platforms (rHyaluronidase and Oncofid™), and our extensive HY-based product offerings in joint healthcare, dermatology and advanced wound care,” states Mr. Giorgio Foresti, CEO of FIDIA Farmaceutici S.p.A. For FIDIA Pharma USA Inc, Mr. Aldo Donati, President of Fidia Pharma USA, states: “The Conference is an excellent venue for partnering discussions as we look to strengthen our presence in the US market and expand our portfolio with new products that are synergic to our flagship product HYALGAN® (sodium hyaluronate, intra-articular injections for the treatment of pain in osteoarthritis of the knee) and our wound care line.”

Dr. Carlo Pizzocaro, President of P&R Holding, the chemical group owner of FIDIA Farmaceutici S.p.A., and Aldo Donati, President of FIDIA Pharma USA Inc. will be present to speak with investors and companies.

FIDIA Farmaceutici S.p.A. is an international integrated Pharma Company based on the extensive know-how on hyaluronan (GAG family) and its proprietary derivatives, with specialized technology platforms, that enable the Company to produce hyaluronic acids with different molecular weights and characteristics, according to the indications designed for the finished products.

The international approach is crucial to the company, whose products are marketed in over 100 markets worldwide, through fully owned subsidiaries and a comprehensive network of alliances and distributors, among which are major players in the pharmaceutical market segments in which Fidia operates.

With its leadership in the development, manufacturing and marketing of unique HY-based products. FIDIA Farmaceutici S.p.A. operates in diverse therapeutic areas, providing a wide array of innovative treatment options – medicinal products, medical devices, nutritional supplements and biomaterials – for application in Joint Healthcare, Advanced Wound Care, Dermatology and Aesthetics.

FIDIA Farmaceutici S.p.A. is part of the P&R Holding, a chemical group operating in the manufacturing of Active Pharmaceutical Ingredients, advanced intermediates, and High Potency Drugs dedicated to diseases with high socio-economic relevance.

More information can be found on our corporate website and US website

Carolyn Kong
Fidia Pharma USA Inc.
Morris Corporate Center 1 – Bldg. C
300 Interpace Parkway
Parsippany, NJ 07054
Tel. +1-973-507-5120

Our Four Leading Principles: